黄酮类化合物及其纳米制剂在肿瘤防治中的研究进展

doi:10.16689/j.cnki.cn11-9349/r.2020.03.021

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (659 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The poor accessibility to tumor tissues and a range of adverse drug reactions are still great concerns for cancer therapies. Flavonoids are documented great potential in combating various types of cancer, while their safety profile and tumor site-specific action have not been evaluated thoroughly. Low solubility, rapid metabolism and poor absorption of dietary flavonoids limit their antitumor activity in vivo. Moreover, flavonoids may interact with other therapeutic agents resulting their bioavailability reduction, especially through biotransformation. Nanocarriers can alter pharmacokinetics and pharmacodynamic profile of incorporating drug. Moreover, nanocarriers are designed for targeted drug delivery, improving the bioavailability of poorly water-soluble drugs, delivery of macromolecules to site of action, and reducing ADRs. It has been shown the potential of flavonoids nano-formulations, especially quercetin, naringenin, apigenin, catechins and fisetin in the prevention and treatment of several types of cancer, both in vitro and in vivo studies. However, few clinical trials have yet to be performed. This review focuses on the impact of flavonoids nano-formulations on the improvement of their bioavailability, therapeutic and safety profile and will open new insights in the field of drug discovery for cancer therapeutics.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2020.03.021 OR http://182.92.200.144/EN/Y2020/V7/I3/362

1.CAI Z, LIU Q. Understanding the Global Cancer Statistics 2018: implications for cancer control［J］. Sci China Life Sci, 2019, 10.1007/s11427-019-9816-1.
2.MILLARD M, YAKAVETS I, ZORIN V, et al. Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening［J］. Int J Nanomedicine, 2017, 12:7993-8007.
3.SAK K. Site-specific anticancer effects of dietary flavonoid quercetin［J］. Nutr Cancer, 2014, 66(2):177-193.
4.CHAHAR M K, SHARMA N, DOBHAL M P, et al. Flavonoids:A versatile source of anticancer drugs［J］. Pharmacogn Rev, 2011, 5(9):1-12.
5.LIU-SMITH F, MEYSKENS F L. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma［J］. Mol Nutr Food Res, 2016, 60(6):1264-1274.
6.GARCIA-LAFUENTE A, GUILLAMON E, VILLARES A, et al. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease［J］. Inflamm Res, 2009, 58(9):537-552.
7.RUENROENGKLIN N, ZHONG J, DUAN X, et al. Effects of various temperatures and pH values on the extraction yield of phenolics from litchi fruit pericarp tissue and the antioxidant activity of the extracted anthocyanins［J］. Int J Mol Sci, 2008, 9(7):1333-1341.
8.PALAFOX-CARLOS H, AYALA-ZAVALA J F, GONZALEZ-AGUILAR G A. The role of dietary fiber in the bioaccessibility and bioavailability of fruit and vegetable antioxidants［J］. J Food Sci, 2011, 76(1):R6-R15.
9.CHEN Z, ZHENG S, LI L, et al. Metabolism of flavonoids in human: a comprehensive review［J］. Curr Drug Metab, 2014, 15(1):48-61.
10.XIAO J. Dietary flavonoid aglycones and their glycosides: Which show better biological significance?［J］. Crit Rev Food Sci Nutr, 2017, 57(9):1874-1905.
11.OZDAL T, SELA D A, XIAO J, et al. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility［J］. Nutrients, 2016, 8(2):78.
12.AMAWI H, ASHBY C J, TIWARI A K. Cancer chemoprevention through dietary flavonoids: whats limiting?［J］. Chin J Cancer, 2017, 36(1):50.
13.GAO S, HU M. Bioavailability challenges associated with development of anti-cancer phenolics［J］. Mini Rev Med Chem, 2010, 10(6):550-567.
14.GUSTAFSON H H, HOLT-CASPER D, GRAINGER D W, et al. Nanoparticle Uptake: The Phagocyte Problem［J］. Nano Today, 2015, 10(4):487-510.
15.WICKI A, WITZIGMANN D, BALASUBRAMANIAN V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications［J］. J Control Release, 2015, 200:138-157.
16.TAVARES A J, POON W, ZHANG Y N, et al. Effect of removing Kupffer cells on nanoparticle tumor delivery［J］. Proc Natl Acad Sci U S A, 2017, 114(51):E10871-E10880.
17.BREGOLI L, MOVIA D, GAVIGAN-IMEDIO J D, et al. Nanomedicine applied to translational oncology: A future perspective on cancer treatment［J］. Nanomedicine, 2016, 12(1):81-103.
18.STYLIANOPOULOS T, POH M Z, INSIN N, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions［J］. Biophys J, 2010, 99(5):1342-1349.
19.TZENG C W, TZENG W S, LIN L T, et al. Enhanced autophagic activity of artocarpin in human hepatocellular carcinoma cells through improving its solubility by a nanoparticle system［J］. Phytomedicine, 2016, 23(5):528-540.
20.KULBACKA J, PUCEK A, KOTULSKA M, et al. Electroporation and lipid nanoparticles with cyanine IR-780 and flavonoids as efficient vectors to enhanced drug delivery in colon cancer［J］. Bioelectrochemistry, 2016, 110:19-31.
21.GHOSH P, SINGHA R A, CHAUDHURY S, et al. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity［J］. Int J Biol Macromol, 2016, 86:408-417.
22.BALAKRISHNAN S, MUKHERJEE S, DAS S, et al. Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231)［J］. Cell Biochem Funct, 2017, 35(4):217-231.
23.CARLSON L J, COTE B, ALANI A W, et al. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity［J］. J Pharm Sci, 2014, 103(8):2315-2322.
24.SABZICHI M, HAMISHEHKAR H, RAMEZANI F, et al. Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling［J］. Asian Pac J Cancer Prev, 2014, 15(13):5311-5316.
25.YUAN Y G, PENG Q L, GURUNATHAN S. Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment［J］. Int J Nanomedicine, 2017, 12:6487-6502.
26.GHOSH A, GHOSH D, SARKAR S, et al. Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats［J］. Eur J Cancer Prev, 2012, 21(1):32-41.
27.FAN J X, ZHENG D W, RONG L, et al. Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis［J］. Biomaterials, 2017, 139:116-126.
28.di LEO N, BATTAGLINI M, BERGER L, et al. A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis［J］. Eur J Pharm Biopharm, 2017, 114:1-10.
29.JAIN S, GARG T, KUSHWAH V, et al. alpha-Tocopherol as functional excipient for resveratrol and coenzyme Q10-loaded SNEDDS for improved bioavailability and prophylaxis of breast cancer［J］. J Drug Target, 2017, 25(6):554-565.
30.XU P, YIN Q, SHEN J, et al. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS［J］. Int J Pharm, 2013, 454(1):21-30.
31.KUMAR S, MEENA R, RAJAMANI P. Fabrication of BSA-Green Tea Polyphenols-Chitosan Nanoparticles and Their Role in Radioprotection: A Molecular and Biochemical Approach［J］. J Agric Food Chem, 2016, 64(30):6024-6034.